343 related articles for article (PubMed ID: 33256355)
21. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
Graham DJ; Izurieta HS; Muthuri SG; Zhang D; Sandhu AT; Lu Y; Zhao Y; Feng Y; Eworuke E; Lyu H; Gandotra C; Smith ER; Avagyan A; Wernecke M; Kelman JA; Forshee RA; MaCurdy TE
J Gen Intern Med; 2021 Dec; 36(12):3802-3809. PubMed ID: 34599472
[TBL] [Abstract][Full Text] [Related]
22. An umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes.
Kurdi A; Mueller T; Weir N
Eur J Clin Invest; 2023 Feb; 53(2):e13888. PubMed ID: 36205627
[TBL] [Abstract][Full Text] [Related]
23. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
[TBL] [Abstract][Full Text] [Related]
24. Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.
Wrona W; Budka K; Filipiak KJ; Niewada M; Wojtyniak B; Zdrojewski T
Kardiol Pol; 2016; 74(9):1016-24. PubMed ID: 27112942
[TBL] [Abstract][Full Text] [Related]
25. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
26. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
Georges JL; Gilles F; Cochet H; Bertrand A; De Tournemire M; Monguillon V; Pasqualini M; Prevot A; Roger G; Saba J; Soltani J; Koukabi-Fradelizi M; Beressi JP; Laureana C; Prost JF; Livarek B
PLoS One; 2020; 15(12):e0244349. PubMed ID: 33347477
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.
Dai YN; Wang JH; Zhu JZ; Lin JQ; Yu CH; Li YM
Cancer Causes Control; 2015 Sep; 26(9):1245-55. PubMed ID: 26081426
[TBL] [Abstract][Full Text] [Related]
28. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
29. Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium.
Peñalvo JL; Genbrugge E; Mertens E; Sagastume D; van der Sande MAB; Widdowson MA; Van Beckhoven D;
BMJ Open; 2021 Sep; 11(9):e053393. PubMed ID: 34531225
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis.
Xu J; Teng Y; Shang L; Gu X; Fan G; Chen Y; Tian R; Zhang S; Cao B
Clin Infect Dis; 2021 Jun; 72(11):e901-e913. PubMed ID: 33079200
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study.
Liu X; Liu Y; Chen K; Yan S; Bai X; Li J; Liu D
J Med Virol; 2021 Feb; 93(2):854-862. PubMed ID: 32687223
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension.
Tian C; Li N; Bai Y; Xiao H; Li S; Ge QG; Shen N; Ma QB
World J Clin Cases; 2021 Jan; 9(1):47-60. PubMed ID: 33511171
[TBL] [Abstract][Full Text] [Related]
34. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
35. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
36. Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial.
Macedo AVS; de Barros E Silva PGM; de Paula TC; Moll-Bernardes RJ; Mendonça Dos Santos T; Mazza L; Feldman A; Arruda GDAS; de Albuquerque DC; de Sousa AS; de Souza OF; Gibson CM; Granger CB; Alexander JH; Lopes RD
Am Heart J; 2022 Jul; 249():86-97. PubMed ID: 35405099
[TBL] [Abstract][Full Text] [Related]
37. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection.
Salah HM; Calcaterra G; Mehta JL
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):503-507. PubMed ID: 32748634
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
39. Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.
Dai XC; An ZY; Wang ZY; Wang ZZ; Wang YR
Front Cardiovasc Med; 2021; 8():609857. PubMed ID: 33981731
[TBL] [Abstract][Full Text] [Related]
40. Associastion of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19.
Vahedian-Azimi A; Rahimibashar F; Najafi A; Kidde J; Shahriary A; Shojaei S; Pourhoseingholi MA; Jamialahmadi T; Sahebkar A
Adv Exp Med Biol; 2021; 1327():205-214. PubMed ID: 34279841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
